Roche has introduced the new Elecsys IGRA SARS-CoV-2 diagnostic test, which helps provide a better understanding of the body’s immune response to SARS-CoV-2 infection and vaccination.

Launched in countries accepting the CE mark, the new test has been designed to detect individuals with an adaptive T-cell response to the SARS-CoV-2 virus, indicating whether the person has immunity protection after infection or vaccination.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It combines the cobas IGRA SARS-CoV-2 Tubes for in vitro T cell stimulation and an automated electrochemiluminescence immunoassay (ECLIA) for interferon-gamma measurement to detect the T cell-mediated immune response to the virus in human whole blood.

The Elecsys IGRA SARS-CoV-2 test provides physicians with information regarding the T cell response of a patient and allows them to make better care decisions.

It uses 189 different SARS-CoV-2 antigens that cover the viral genome and host HLA subtypes. The assay has been developed for robustness against viral variants and population diversity.

Roche Diagnostics CEO Thomas Schinecker said: “The Elecsys IGRA SARS-CoV-2 test can provide a deeper understanding into immune response.

“This, in turn, may help to understand and identify those at higher risk of progressing to severe disease during an existing or future infection.

“This is particularly important in immunocompromised and high-risk patient groups that represent up to 20% in a given population.”

The company stated that the launch of the Elecsys IGRA SARS-CoV-2 test adds another important diagnostic solution to its portfolio of Covid-19 solutions, which have been developed to assist public health authorities, health care providers and patients in the fight against the pandemic.

Last month, the company’s Elecsys Amyloid Plasma Panel received breakthrough device designation from the US Food and Drug Administration (FDA).